Loss of STK11 function was identified as a potential feature of malignant tumors in a variety of malignancies, such as cervical cancer (23), meningiomas (24), cholangiocarcinoma (25) and lung cancer (13). This evidence concerns the gene STK11 and cholangiocarcinoma.